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ABSTRACT
We postulated that fludarabine (Flu) instead of cyclophosphamide (Cy) combined with i.v. busulfan (Bu) as pre-
conditioning for allogeneic hematopoietic stem cell transplantation (HSCT) would improve safety and retain
antileukemic efficacy. Sixty-seven patients received BuCy2, and subsequently, 148 patients received Bu-Flu.
Weused a Bayesianmethod to compare outcomes between these nonrandomized patients. The groups had com-
parable pretreatment characteristics, except that Bu-Flu patients were older (46 versus 39 years, P\ .01), more
often had unrelated donors (47.3% versus 20.9%, P\ .0003), and had shortermedian follow-up (39.7 versus 74.6
months). To account for improved supportive care and other unidentified factors that may affect outcome (‘‘pe-
riod’’ effects), 78 acute myelogenous leukemia (AML) patients receivingMelphalan-Flu (MF), treated in parallel
during this time (1997-2004) were used to estimate the period effect. TheMF patients’ outcomes worsened dur-
ing this period. Therefore, the period effect is unlikely to explain the greatly improved outcome with Bu-Flu.
Patients transplanted with Bu-Flu in the first complete remission (CR1) had a 3-year overall survival and
event-free-survival (EFS) of 78% and 74%, respectively, whereas CR1 patients younger than age 41 had a 3-
year EFS of 83%. These results support replacing BuCy ± ATG with Bu-Flu ± rabbit-antithymocyte globulin
(ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolida-
tion chemotherapy for AML in CR1.
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Introduction of i.v. Busulfan (i.v. Bu) as an alterna-
tive to oral Bu [1] rekindled interest in optimizing the
conditioning regimen to improve treatment outcome
after allogeneic hematopoietic stem cell transplanta-
tion (HSCT) for myelogenous leukemia [2-5]. Recent
studies with i.v. Bu and cyclophosphamide (Cy) sug-
gested a lower incidence of serious hepatic veno-occlu-
sive disease (VOD) and other treatment-related
serious adverse events compared to what would be ex-
pected after oral BuCy2 [6,7]. These risks are of partic-
ular concern because typically Bu is combined with672other agent(s), for example, Cy, known to cause
VOD [8,9]. However, not only regimen-related toxic-
ity, but also engraftment and acute graft-versus-host
disease (aGVHD) may be influenced by variable sys-
temic exposure [6,7,10,11] and the relative timing of
the individual cytotoxic agent(s) in a high-dose chemo-
therapy combination [12-14]. This is especially true
when alkylating agents with partly overlapping dose-
limiting toxicities are combined in myeloablative pre-
transplant conditioning therapy. We thus decided to
combine i.v. Bu with an immunosuppressive agent
having very limited hepatotoxic potential, fludarabine
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tures; Flu is likely as immunosuppressive as Cy [15]
and, when timed appropriately, it synergistically pro-
motes Bu-induced cytotoxicity through interference
with repair of XRT- and alkylator-induced DNA-
damage [16]. Further, Flu does not cause VOD, and
its long plasma half-life encourages once daily admin-
istration. We recently reported safety and outcome
data after HSCT for acute myelogenous leukemia
(AML)/myelodysplastic syndrome (MDS) with a mye-
loablative, once daily i.v. Bu-Flu regimen [17], and
similarly encouraging data have been obtained in
patients undergoing allogeneic HSCT for a variety
of hematologic malignancies [18,19]. These early re-
ports demonstrate i.v. Bu-Flu combinations to be
safe and efficacious, resulting in low treatment-related
mortality (TRM) because of, at least in part, highly re-
producible intra- and interpatient systemic Bu expo-
sure [17,18,20,21]. Although the available safety and
efficacy data appear promising, there was apprehen-
sion about possibly suboptimal antileukemic efficacy
of Flu compared with Cy, particularly in patients
with active leukemia at the time of transplant [4]. Ide-
ally, this question would be addressed through a com-
parison of BuCy2 and Bu-Flu in a randomized phase
III study, stratifying patients for clinical disease stage
and other prognostic factors. However, aside from
the large number of patients and long time needed to
complete such a study, it would also be fraught with
uncertainty as to whether fixed dose Bu delivery is op-
timal; an ongoing study at the M.D. Anderson Cancer
Center is comparing fixed-dose Bu with drug delivery
based on patient-specific pharmacokinetic (PK) infor-
mation. Further comparisons of clinical outcome and
systemic Bu exposure suggest the presence of an opti-
mal therapeutic interval for i..v. Bu in combination
with either Cy or Flu [11,22]. Because this issue is un-
resolved, and PK-guided dosing currently is being re-
fined, it is premature to begin a long-term study of
fixed dose Bu-Flu versus BuCy2.
In the present analysis, we compared the outcomes
of 67 patients receiving BuCy2 with 148 consecutive
patients treated subsequently with the fixed-dose Bu-
Flu combination. We observed a remarkable differ-
ence in TRM rates between the 2 groups, both within
the first 100 days and at 1 year posttransplant. This low
early TRM after Bu-Flu was strikingly different from
previous experience by both our group and that of
others with alternative conditioning regimens [23-28].
However, comparison of Bu-Flu and BuCy2 based
on these new data was complicated by several issues.
First, there were significant differences in age and
other characteristics of the 2 patient populations. Sec-
ond, andmore importantly, patients were not random-
ized between the 2 conditioning regimens; rather, the
programs were executed sequentially during an 8-year
period: 1997-2001 for the Bu Cy2 trial and 2001-2005for the Bu-Flu trial. Consequently, the difference be-
tween BuCy2 and Bu-Flu—the ‘‘treatment effect’’—
is confounded by possible differences between the
patient groups or therapeutic environments in these
2 time periods that are unrelated to the preparative
regimens, including changing practice patterns such
as addition of new antibacterial, antifungal, and anti-
viral antibiotics, introduction of rabbit antithymo-
cyte-globulin (ATG), changing referral patterns,
differences in patient characteristics, or the effects of
other, unknown variables. We will refer to the com-
posite influence of all such confounding factors as
the ‘‘period’’ effect. The statistical problem thus is to
compare treatment effects between 2 treatment groups
while accounting for the confounding between-trial
effects. We will do this, using a Bayesian model and
method [2,29,30] that deals with treatment-trial con-
founding, by estimating the period effect using a sepa-
rate data set of 78 patients who received pretransplant
conditioning therapy with Melphalan and Flu (MF) at
M.D. Anderson during the period 1997 to 2004 [26],
and assuming that the period effect for the BuCy2
and Bu-Flu patients was the same as for the MF pa-
tients. Although this Bayesian approach is not a substi-
tute for a randomized phase III trial, it can be used to
obtain a reasonable estimate of treatment effect(s) un-
der the assumption that period effect accounts for be-
tween-trial effects. The results may be used to decide
whether to compare these regimens in a prospective
randomized trial. Additionally, although ongoing
studies of individualized, PK-guided i.v. Bu (combined
with Flu6 ATG) are completed, our analyses also can
be used to support therapeutic decision making in
patients with AML/MDS who are considered for
allogeneic HSCT using i.v. Bu-based conditioning
therapy. Presently, our analyses strongly support (1)
Bu-Flu 6 ATG as a preferred regimen over i.v.
BuCy26ATG, and (2) a prospective comparison of al-
logeneic HSCT with conventional chemotherapy in
first complete remission (CR1) for patients with AML.
PATIENTS AND METHODS
Patient Eligibility
AML patients should have failed initial induction
chemotherapy, or have high-risk disease in CR1,
characterized by cytogenetics other than translocation
(t)(8;21), inversion (inv)16, or t(15;17), or by the need
for more than 1 cycle of chemotherapy to achieve CR
[31]. Patients beyond CR1 were also eligible. Subjects
with MDS were eligible if they had a high Interna-
tional Prognostic Score System (IPSS) score ($2)
[32], or if they progressed after chemotherapy.
The eligibility criteria included acceptable renal
(creatinine #1.5 mg%) and hepatic function with
normal bilirubin, SGPT #3 times the upper normal
limit, a ZUBROD performance status #2, negative
674 B. S. Andersson et al.serology for hepatitis B and C, and HIV, LVEF
$45%, FEV1, FVC, and DLCO $50% of predicted,
absence of uncontrolled infection, and no chemother-
apy within 30 days prior to entry. A human leukocyte
antigen (HLA) compatible related (fully matched or
1-antigen mismatched) or matched unrelated donor
(MUD) was required. All patients signed informed
consent according to institutional guidelines. One
Bu-Flu patient was treated off protocol with institu-
tional review board approval, under a ‘‘compassionate
plea’’ mechanism because of chronic renal failure de-
veloped after a previous nonmyeloablative transplant.
No patients treated after August 2005 were included
in this study to allow for comparison of patient popu-
lations with a median follow-up .2 years.
Conditioning Regimens
I.V. Bu-Flu. The treatment has been previously de-
scribed [17], and consisted of Flu (Fludara, Berlex
Laboratories, Inc., Montville, NJ) 40 mg/m2 given
over 60 minutes daily for 4 days, each dose
immediately followed by i.v. Bu (IV Busulfex (busul-
fan) Injection, ESP Pharma, Inc., Edison, NJ), 130
mg/m2 over 3 hours daily (days –6 to –3).
I.V. BuCy2. This regimen was also previously de-
scribed [33]. Briefly, i.v. Bu was administered at 0.8
mg/kg (32 mg/m2) over 2 hours every 6 hours for
16 doses (days –7 to –4) and Cy was then given at 60
mg/kg i.v. over 1 hour daily for 2 doses (days –3 and –2).
MF. In the MF group the patients were treated with
Flu 25 mg/m2 i.v. daily for 5 days and melphalan 90
mg/m2 or 70 mg/m2 daily for 2 days as described by
Giralt et al. [26]. Melphalan was given after Flu on
the last 2 days of chemotherapy. Day zero was the
day of transplantation in all protocols. In late 2004,
this program was revised to incorporate gemtuzumab
ozogamicin [34]. Patients treated on this revised MF
protocol were not included in the current comparison.
Patients were eligible for the MF program if they were
older than 55 years and/or having at least 1 comorbid
condition that made them ineligible for the front-line
program (BuCy2 and Bu-Flu, respectively).
Supportive Care
All supportive care measures were utilized accord-
ing to extant institutional protocols. All patients
received Filgrastim (Neupogen, Amgen, Inc.,
Thousand Oaks, CA) 5 mg/kg subcutaneously daily
from day 17 until achieving an absolute neutrophil
count (ANC) $1.5  109/L for 3 days. Phenytoin
was used during and 1 day after i.v. Bu-based therapy.
The cytotoxic drugs were infused via a controlled-
rate infusion pump through a central venous catheter.
Flu dosing was according to actual body weight. The
alkylating agents were dosed per patients’ actual
weight up to 120% of ideal body weight, above whichthe doses were based on adjusted ideal body weight
(ideal weight plus 50% of the difference between ideal
and actual weight). All groups received graft-versus-
host disease (GVHD) prophylaxis with tacrolimus
(Prograf, Fujisawa Healthcare, Inc., Deerfield, IL)
and minidose methotrexate (MTX) 5 mg/m2 on days
1, 3, 6, and 11 following transplant [35]. Tacrolimus
was to be continued for 6-8 months. Patients with
a 1-antigen mismatched related or an unrelated donor
received equine ATG (ATGAM, Pharmacia & Up-
john Company, Kalamazoo, MI) 20 mg/kg daily
(days –3 to –1 (in the BuCy2 group), or rabbit-ATG
(Thymoglobulin, Genzyme Inc., Cambridge, MA),
0.5 mg/kg on day –3, 1.5 mg/kg on day –2, and 2.0
mg/kg on day –1) (Bu-Flu group). In addition, Pentos-
tatin (Nipent, Supergen,Dublin, CA)was added in 10
cases receiving unrelated (n 5 8) or 1-antigen mis-
matched related donor grafts (n5 2), under an investi-
gational protocol (i.v. Bu-Flu arm only). The dose of
pentostatin was 0.5 mg/m2 (n 5 2), 1 mg/m2 (n 5 4),
and 1.5 mg/m2 (n 5 4) given on days 8, 15, 22, and
30 following HSCT.
Hematopoietic Stem Cell Grafts
Procurement of donor peripheral blood progenitor
cells (PBPC) has been described [36]. Donors were
treated with Filgrastim 10-12 mg/kg every 12 hours
over 3 days and in the morning of day 4 prior to
PBPC collection. The donor’s total blood volume was
processed3 timesper apheresis procedure. In case a sec-
ond apheresis procedure was performed, Filgrastim
treatment was continued through prior to the second
procedure. The PBPC dose was targeted to approxi-
mately 5  106 CD341 cells/kg patient body weight,
in keeping with the observation of a correlation be-
tween higher cell doses and incidence of GVHD [37].
BonemarroworPBPC fromunrelated donorswere ob-
tained through the National Marrow Donor Program.
HLATyping
HLA typing for class I antigens was performed
using standard serologic techniques. Class II alleles
(HLA-DRB1) were resolved with low-resolution mo-
lecular typing using sequence specific oligonucleotide
primers for hybridization of amplified DNA, followed
by high-resolution typing in all patients and donors.
Donor-recipient pairs were considered fully matched
by compatibility for HLA-A, -B, and -DRB1.
Analysis of Chimerism
Peripheral blood or bone marrow donor-recipient
chimerism was evaluated by analysis of DNA microsa-
tellite polymorphisms by polymerase chain reaction
(PCR) with D6S264, D3S1282, D18S62, and
D3S1300 fluorescence-labeled primers, and analyzed
using GeneScan software (Applied Biosystems, Foster
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netic analysis with G-banding or fluorescein in situ
hybridization studies for the Y-chromosome in sex-
mismatched cases. Mixed chimerism was defined as
the presence of any detectable ($1%) recipient DNA
or cells in addition to donor-derived DNA or cells.
Clinical Outcome Variables
Time of engraftment was defined as the first of 3
consecutive days with ANC $0.5  109/L. Failure to
engraft in the absence of malignancy by day 130 was
considered primary engraftment failure. Secondary
graft failure was initial engraftment with documented
donor-derived hematopoiesis followed by loss of graft
function without recurrent malignancy. Time of plate-
let engraftment was defined as the first of 7 consecutive
days with a platelet count$20  109/L without trans-
fusion support. Criteria for CR prior to transplant
included absence of circulating blasts,\5% marrow
blasts, lack of chromosomal abnormalities, and platelet
count $100  109/L. CR posttransplant was defined
using the same criteria except for platelet count, with
documented donor cell engraftment.
Cytogenetics were considered prognostically favor-
able for patients with t(15,17), inv 16, or t(8,21); poor
risk (‘‘bad’’) for patients with deletions of chromosome
5 and/or 7, multiple chromosomal abnormalities or tri-
somy of chromosome 8; and intermediate risk in all
others [31]. Standard morphologic criteria, conven-
tional cytogenetics, or both were used to diagnose re-
current disease. Cytogenetic relapse was documented
by the presence of a clonal chromosomal abnormality
in .2 consecutive tests, taken at least 4 weeks apart.
Time to relapse/progressive disease was calculated
from transplant to the day of documented event. Pa-
tients who did not achieve a CR after transplant were
scored as failures at the date of the documented persis-
tent disease. Toxicity was scored using the modified
National Cancer Institute criteria (CTC 2.0).
Overall survival (OS)was calculated from the day of
transplant, with patients alive at the time of last follow-
up administratively censored. TRM was defined as
death because of any cause other than relapse, whereas
nonrelapse-related survival (NRRS) was defined as the
time from HSCT to death for reasons other than re-
lapse, with relapse being a censoring event. Event-free
survival (EFS) time was counted from day zero to re-
lapse or death. Relapse-free survival (RFS) was defined
as time fromHSCT to relapse with death or time of last
follow-up in CR counting as censoring events.
Adverse events and hematologic parameters were
monitored daily, clinical chemistry parameters at least
twice weekly during the initial hospitalization and then
at least once weekly up to HSCT day 1100. Subse-
quently, patients were followed at least quarterly dur-
ing the first year, then at gradually increasing intervals.Statistical Methods
General methods. Patient characteristics were
summarized using the median (range) for numeric
variables or frequencies (percentages) for categoric
variables. Differences in the distributions of patient
characteristics between groups were assessed using
Kruskal-Wallis or generalized Fisher exact tests [38].
Unadjusted probabilities of event times were estimated
using the method of Kaplan and Meier (KM) [39]. The
log-rank test [40] was used to compare unadjusted OS,
NRRS, EFS, and RFS between subgroups. Bayesian
log-normal regression models were used to assess the
joint effects of patient covariates and treatments on
OS, and similarly on each of the other outcomes
NRRS, EFS, and RFS. The covariates included cytoge-
netics (bad versus other), disease status at BMT (in CR
versus not in CR), donor type (sibling or other-related
versus unrelated donor), age, whether any blasts were
present in the patient’s peripheral blood (PB), and PB
platelet count. The log-normalmodel was selected after
assessing goodness of fit for several parametric models,
including the exponential, Weibull, and log-logistic,
using the Bayesian Information Criterion (BIC) and
the Bayesian chi-squared method [41]. The log-normal
model assumes a normal distribution for the log-trans-
formed event time, denoted log(T)N(m, r), where m is
a linear combination of covariate effects and treatment
effects, and r is the precision parameter, equal to the in-
verse of the variance, s2, of log(T).
For each model fit, we assumed that each parame-
ter in m followed a noninformative normal prior with
mean 0 and variance 1000, and a noninformative in-
verse-Gamma prior for s2, with mean 1 and variance
1000. All statistical analyses were carried out in Splus
6.1 [42] or, for the Bayesian model fits, in WinBugs
1.4 [43].
Bayesian method for comparing Bu-Cy versus
Bu-Flu. Patients were not randomized between Bu-
Flu and BuCy2 with all BuCy2 patients enrolled prior
to t*5 4/18/2001 and all Bu-Flu patients enrolled after
this date. Consequently, the Bu-Flu versus BuCy2
(‘‘treatment’’) effect was confounded with the post-t*
versus pre-t* (‘‘period’’) effect in the data from the
215 patients, and this treatment effect cannot be
estimated from these data. To address this problem,
we first fit a Bayesian log normal regression model to
the data from the 215 BuCy2 and Bu-Flu patients, in-
cluding patient prognostic covariates and a parameter
q accounting for the confounded treatment-period
effect by including an indicator [Bu-Flu] in the linear
term m. We assumed that this parameter was the sum
of the actual Bu-Flu-versus-BuCy2 (treatment) effect,
qTRT, and a period effect, qPERIOD, formally, q5 qTRT
1 qPERIOD. We also fit a similar Bayesian regression
model, including the same covariates and an indicator
[PERIOD] 5 1 if the patient was enrolled after t* and
676 B. S. Andersson et al.0 if before t*, to the data on the 78 MF patients treated
over a period of time spanning the 2 periods both
before and after t*. Because this provided a posterior
estimate of qPERIOD, we obtained the treatment effect
of interest as qTRT 5 q2 qPERIOD. That is, under the
above additivity assumption that the confounded effect
of Bu-Flu after t* versus BuCy2 before t* was equal to
the sum of the Bu-Flu versus BuCy2 treatment effect
plus the post-t* versus pre-t* period effect, the period
effect was estimated separately, and the i.v. Bu-Flu ver-
sus i.v. BuCy2 effect was obtained by subtraction
[2,30]. All treatment-covariate interactions were in-
cluded initially in the model, and interaction terms
for which the posterior probability of a beneficial effect
was not either .0.90 or\0.10 were dropped.
RESULTS
Patients Treated with BuCy2 versus Bu-Flu
(N 5 215)
Table 1a summarizes characteristics of the 215
BuCy2 and Bu-Flu patients. The only significant cova-
riate imbalances were that the Bu-Flu patients were on
average 7 years older and had a lower percentage of
Sib/related donors (52.7% versus 79.1%). In terms of
age and donor type, therefore, because patients were
not randomized between the 2 regimens, the Bu-Flu
group would be at a disadvantage in any statistical
comparison that does not account for these covariates.
Only a minority of patients were transplanted while in
any CR (47.8% of BuCy2 patients and 46.6% of the
Bu-Flu patients).
Patients Treated with MF (N 5 78)
Table 1b summarizes patient characteristics of the
78 MF patients. The only significant imbalance within
the group was that the MF patients treated after April
18, 2001, had a higher fraction of patients transplanted
in CR, compared with those treated before April 18,
2001 (35.7% versus 12.0%).
Unadjusted Analyses
OS. For this analysis, the event was defined as death
from any cause. Among the 215 i.v. Bu patients, 120
(55.8%) died (47 [70%] in the BuCy2 group and 73
[49%] in the Bu-Flu group). The median OS time
was 24.6 months (95% confidence interval [CI] 16.6-
51.1 months). The median follow-up time was 74.6
months (95% CI 69.8-83.6 months) for the BuCy2
group and 39.1 months (95% CI 36.7-45.4 months)
for the Bu-Flu group. Figure 1a shows the Kaplan-Me-
ier estimates for OS in these 2 groups, indicating that
the Bu-Flu patients survived significantly longer, but
had a shorter follow up time.
EFS. For this analysis, the event was defined as pro-
gression or death from any cause. Among the 215 i.v.
Bu patients, 133 (61.9%) progressed or died (50BuCy2 patients and 83 Bu-Flu patients). The median
EFS time was 11.8 months for the whole group
(95% CI, 7.6-20 months). Figure 1b shows the Ka-
plan-Meier estimates for the EFS in these 2 groups, in-
dicating that the Bu-Flu patients had a longer EFS,
compared with the BuCy2 group (19.1 months versus
8.4 months, respectively).
NRRS. For this analysis, the event was defined as
death without disease recurrence. Among the 215
Bu-treated patients, 36 (16.7%) died of treatment-re-
lated causes and without recurrent disease (18,
26.9%, of the BuCy2 and 18, 12%, of the Bu-Flu pa-
tients). The median NRRS time has not been reached
Table 1a. Patient Characteristics by Treatment Group in Patients
Treated with BuCy2 or Bu-Flu
Variable BuCy2 (N 5 67)* Bu-Flu (N 5 148) P-Value
Cytogenetics 1.00
Others 47 (70.1) 104 (70.3)
Bad 20 (29.9) 44 (29.7)
Disease Status .88
Others 35 (52.2) 79 (53.4)
CR 32 (47.8) 69 (46.6)
CR1 12 (18) 36 (24)
Allo type .0003
Others 14 (20.9) 70 (47.3)
Sib/related 53 (79.1) 78 (52.7)
PB blast .11
.0 24 (35.8) 37 (25.0)
0 43 (64.2) 111 (75.0)
Age 39 (13-64) 46 (19-66) .01
PB PLT 86 (2-330) 89 (3-463) .41
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic;
Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.
*Number in each cell is N (%) for categoric variable and median
(range) for continuous variable.
Table 1b. Patient Characteristics by Treatment Group in Patients
Treated with MF
Variable
Before
4/18/2001 (N 5 50)*
After
4/18/2001 (N 5 28) P-Value
Cytogenetics .16
Others 23 (46.0) 18 (64.3)
Bad 27 (54.0) 10 (35.7)
Disease Status .02
Others 44 (88.0) 18 (64.3)
CR 6 (12.0) 10 (35.7)
Allo type .24
Others 32 (64.0) 14 (50.0)
Sib/related 18 (36.0) 14 (50.0)
PB blast .08
.0 19 (38.0) 5 (17.9)
0 31 (62.0) 23 (82.1)
Age 54 (23-66) 54 (22-74) .69
PB PLT 46 (2-284) 54 (9-377) .16
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic;
Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.
*Number in each cell is N (%) for categoric variable and median
(range) for continuous variable.
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estimates for the NRRS in these 2 groups, indicating
that the Bu-Flu patients had a longer NRRS time,
compared to the BuCy2 group; the estimated NRRS
at 3 years was 86% in the Bu-Flu group and 66% in
the BuCy2 group.
RFS. For this analysis, the event was defined as
death because of persistent or recurrent disease, with
all other terminating events considered to be right
(administrative) censoring. Among the 215 I.V. Bu pa-
tients 84 (39.1%) died of persistent or recurrent dis-
ease, 55 (37%) of the Bu-Flu patients, and 29 (43%)
of the BuCy2 patients. The median RFS time has not
been reached (95% CI 38.6-NA). Figure 2b shows
the Kaplan-Meier estimates for the RFS in these 2
groups, indicating that there was no significant differ-
ence between the i.v. Bu-Flu and i.v. BuCy2 patients in
terms of RFS. Bearing in mind, again, that patients
were not randomized, and moreover, that KM curves
ignore covariate effects, it is notable that the plateau
for the Bu-Flu RFS curve is about 0.10 higher than
that of the BuCy2 RFS curve.
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Figure 1.Kaplan-Meier estimates for the probabilities of (a) OS, and
(b) EFS by treatment group in 215 patients treated with BuCy2 (- - -
-) and Bu-Flu (—) (the numbers within parenthesis indicate number
of events and cohort size).Early Disease, CR1 Patients
Patients transplanted in CR1 constituted only
a small subgroup (Table 1a), 12 (18%) in the BuCy2
group and 36 (24%) of the Bu-Flu patients. However,
the most striking differences in outcome were encoun-
tered when comparing these subgroups; the 3-year OS
was 78% after Bu-Flu and 42% after BuCy2, and the
3-year EFS percentages were 74% and 42%, respec-
tively (Figure 3a and b). Further, there were no differ-
ences in outcome related to the use of matched related
versus unrelated donors (data not shown). Young
patients (up to and including age 40), fared even better
with Bu-Flu; their 3-year OS and EFS were 94% and
83%, respectively (Figure 3c and d). Finally, the
1-year TRM for patients transplanted in CR using
the Bu-Flu program was 6%, significantly better than
that achieved with the BuCy2 regimen (21%).
GVHD
The overall incidence of aGVHD grades II-IV was
33.3% after BuCy2, 26.1% after Bu-Flu, and 42.1%
p-value = 0.02
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Figure 2.Kaplan-Meier Estimates for the probabilities of (a) NRRS,
and (b) RFS, by treatment group in 215 patients treated with BuCy2
(- - - -) and Bu-Flu (—) (the numbers within parenthesis indicate
number of events and cohort size).
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Figure 3. Survival of patients transplanted in CR1, ‘‘early disease’’ with BuCy2 (- - - -) and Bu-Flu (—); (a) OS, and (b) EFS in all CR1 patients. In
graphs (c) OS, and (d) EFS is depicted for patients up to and including 40 years of age (the numbers within parenthesis indicate number of events
and cohort size).after the MF regimen. Among patients who had a fully
HLA-matched related donor the incidence of aGVHD
grades II-IV was 32.7% after BuCy2, 15.8% after Bu-
Flu, and 25% after MF. The corresponding incidence
of extensive chronic GVHD (cGVHD) was 36.1% af-
ter BuCy2, 34.1% after Bu-Flu, and 39.4% after MF.
Covariate Adjusted Analyses
Table 2a summarizes a fitted Bayesian log-normal
survival model for OS for the 215 i.v. Bu patients, in-
cluding 67 treated with BuCy2 and 148 who received
Bu-Flu. Table 2b summarizes a similar model fit to
the data from the 78 MF patients, with a period effect
in place of the confounded Bu-Flu-versus-BuCy2 treat-
ment effect. Assuming, as described above, that this
time period effect was distributed in a similar fashion
in the FM and BuCy2-Bu-Flu data sets, the posterior
distribution of the treatment effect obtained by sub-
tracting the period effect is summarized in Figure 4a,
which indicates that, after accounting for the period ef-
fect, i.v. Bu-Flu was greatly superior to i.v. BuCy2 interms of OS. Remarkably, even the uncorrected Bu-
Flu-versus-BuCy2 effect favored Bu-Flu over BuCy2
(Table 2a), despite the fact that the MF data showed
a detrimental effect of the later period 2001-2004
when most of the Bu-Flu trial was conducted. Similar
analyses are given in Table 3 and Figure 4b for EFS,
and Tables 4 and Figure 5a for NRRS. Table 5 and
Figure 5b examine the relationship between treatment
arm (BuCy2 versus Bu-Flu) and RFS. After accounting
for covariates and subtracting the period effect in the
Bayesian analyses, the posterior probability that Bu-
Flu is superior to BuCy2 in terms of NRRS is .0.99
and in terms of RFS is only 0.17. It may be argued
that, because nondisease-related and disease-related
deaths are competing risks, Bu-Flu has a much lower
overall death rate but may result in a slightly higher
death rate because of recurrent disease.
DISCUSSION
Several investigators have reported a dose-
response relationship between the pretransplant
Intraveneous Busulfan-Fludarabine Is Superior to i.v. BuCy2 as Pretransplant Conditioning Therapy 679Table 2a. Fitted Bayesian Log-Normal Survival Model for Overall Survival of 215 Patients, Including 67 Patients Treated with BuCy2 and 148 Treated
with Bu-Flu
Posterior 95% Credible Interval
Probability of a
Beneficial EffectVariable Mean SD 2.50% 97.50%
Intercept 2.372 0.563 1.263 3.474 —
Cyto 5 bad (versus other) 20.114 0.277 20.657 0.433 0.339
Disease status 5 CR (versus not in CR) 0.241 0.339 20.431 0.903 0.764
Allo type5 sib/other Rel (versus unrelated) 0.647 0.273 0.109 1.195 0.991
Age 20.023 0.011 20.045 20.001 0.020
PB Blast 5 0 (versus .0) 1.129 0.319 0.494 1.778 1.000
PB PLT 0.003 0.001 0.000 0.006 0.990
Confounded Bu-Flu (versus BuCy2) effect 0.591 0.292 0.015 1.164 0.977
R 0.363 0.054 0.268 0.478
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic; Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.conditioning regimen and long-term outcome after al-
logeneic HSCT in acute leukemia [3,4,10,12,28]. In
this context, i.v. Bu provides a valuable tool for safe
and reproducible delivery of intensive conditioning
treatment; the intra- and interindividual variability in
systemic Bu exposure is considerably lower than
what is typically obtained with oral Bu [17,20,21,44].
Nonrandomized comparisons between patients condi-
tioned with i.v. Bu-based [7,19] and those receiving
oral BuCy2 [6], or TBI-based therapy [27,28], ap-
peared favorable for the i.v. Bu-based combinations
relative to a lower TRM/increased safety. The main
benefit was seen in terms of increased safety/lower
TRM at 100 days and at 1 year posttransplantation
[6,7,17,19,27]. The experience of both our group
[17,45], and that of Russell et al. [18,19], suggested
that (minor) variants of this Bu-Flu 6 ATG combina-
tion would be well-tolerated and safe, reduced-toxicity
myeloablative conditioning treatments. There was
some concern, however, that the ‘‘favorable’’ compar-
ison between i.v. Bu-Flu and i.v. BuCy2 constituted
a nonrandomized assessment of sequential condition-
ing programs during a time when supportive care
had improved in a way that greatly favored the more
recent program. A similar quandary was highlighted
by Chae et al. [46], who reported on a favorable out-come when comparing Bu-flu to BuCy2 in a mixed
patient population transplanted for a variety of hema-
tologic malignancies. Although these authors reported
a greatly improved outcome after Bu-Flu, their analy-
sis was complicated by reporting observations made in
a mixed-patient population with varying ages, per-
formed as 2 sequential programs, and further by
changing from oral to i.v. Bu and then changing Cy
to Flu, all of which may unpredictably contribute to
the final clinical observations. The classical approach
to comparison of different treatment programs is to
perform a prospective randomized trial to obtain an
unbiased estimate of the difference in treatment ef-
fects. Although this ideal route is frequently used,
a large body of data results from single arm trials, as was
the present case. Any comparison of such single-arm,
consecutive trials will suffer from the confounding
effect(s) of unknown factors, here including possible
changes in referral patterns, improved supportive care
routines with introduction of new antifungal, antivi-
ral, and antibacterial agents as well as use of rabbit-
ATG, and increasing experience of the nursing and
medical staff. We have argued that a Bayesian sensi-
tivity analysis can provide a basis for a comparative
evaluation of different treatment programs in the pres-
ence of such confounding effects [2,29]. In the presentTable 2b. Fitted Bayesian Log-Normal Survival Model for Overall Survival of 78 Patients Treated with MF
Posterior 95% Credible Interval
Probability of
a Beneficial EffectVariable Mean SD 2.50% 97.50%
Intercept 3.370 1.437 0.523 6.237 —
Cyto 5 bad (versus other) 20.878 0.500 21.875 0.087 0.038
Disease status 5 CR (versus not in CR) 1.377 0.708 0.012 2.798 0.976
Allo type5 sib/other rel (versus urelated) 0.550 0.506 20.451 1.558 0.865
Age 20.023 0.025 20.072 0.026 0.169
PB Blast 5 0 (versus .0) 0.770 0.559 20.323 1.875 0.919
PB PLT 0.001 0.002 20.003 0.004 0.679
After 04/01 (versus before 04/01) 20.811 0.573 21.945 0.313 0.078
R 0.250 0.056 0.151 0.371 —
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic; Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.
680 B. S. Andersson et al.Table 3. Fitted Bayesian Log-Normal SurvivalModel for Event-Free Survival in 215 Patients, Including 67 Patients Treated with BuCy2 and 148 Treated
with Bu-Flu
Posterior 95% Credible Interval
Probability of
a Beneficial EffectVariable Mean SD 2.50% 97.50%
Intercept 1.622 0.583 0.491 2.752 —
Cyto 5 bad (versus other) 20.090 0.287 20.660 0.473 0.386
Disease status 5 CR (versus not in CR) 0.501 0.341 20.158 1.162 0.932
Allo type 5 sib/other rel (versus unrelated) 0.230 0.279 20.320 0.781 0.799
Age 20.011 0.011 20.033 0.012 0.171
PB Blast 5 0 (versus .0) 1.307 0.336 0.650 1.965 1.000
PB PLT 0.002 0.001 0.000 0.004 0.961
Confounded Bu-Flu (versus BuCy2) effect 0.416 0.295 20.141 1.011 0.922
R 0.327 0.045 0.248 0.424 —
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic; Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.investigation, we exploited the data from the separate
MF trial, a program that remained unaltered from
1997-2004 [26], by estimating the combined con-
founding factors as a ‘‘period’’ effect using theMF trial
data. We assumed that the ‘‘period’’-related changes
that influenced treatment outcome for theMF patients
would similarly influence outcome for patients allo-
cated to the BuCy2 and Bu-Flu regimens over time,
because there was no systematic bias in allocating pa-
tients to the MF regimen versus that of the Bu-based
regimens during this time period.Moreover, all 3 trials
were conducted in the same institution. It may be ar-
gued on fundamental grounds that patients treated
more recently should have benefited from more ad-
vanced supportive care routines, more highly skilled
medical staff, etc. After accounting for known patient
characteristics in the analysis of the MF data, however,
both OS and the chance for RFS worsened over time,
indicating that the remaining period effect favored
the earlier period (1997-2001) over the later time pe-
riod. Thus, improvements in supportive care were ap-
parently more than balanced out by a changing
referral pattern, an increasing median patient age, in-
creasing use of alternative donors and possibly other,
unknown factors. Given that the estimated period ef-
fect greatly favored the earlier period, when the
BuCy2 trial was conducted, it is quite remarkable
that even the uncorrected, confounded Bu-Flu-ver-
sus-BuCy2 effect (Table 2 and Figures 1a, 2b, and 3a
and b) showed Bu-Flu to be a superior regimen.
Our Bayesian analyses led to the conclusion that
the observed differences in 100-day and 1-year mortal-
ity rates between the BuCy2 and Bu-Flu regimens are
likely attributable to a superior safety and tolerance
profile of the latter program in patients with AML/
MDS. In reference to a low TRM, this conclusion is
further supported by Russell et al. [18], who reported
similar findings both in patients with advanced hema-
tologic malignancies, and more recently, in better
prognosis patients with AML and ALL [19]. Thep=0.985
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Figure 4. Posterior distribution under the lognormal regression
model for (a) OS, and (b) EFS of the corrected Bu-Flu versus
BuCy2 treatment effect. In these plots, p denotes the probability of
a beneficial effect of Bu-Flu versus BuCy2, and is represented by
the area of the shaded region in the respective figure.
Intraveneous Busulfan-Fludarabine Is Superior to i.v. BuCy2 as Pretransplant Conditioning Therapy 681Table 4. Fitted Bayesian Log-Normal SurvivalModel for Nonrelapse-Related Survival (NRRS) in 215 Patients, Including 67 Patients Treated with BuCy2
and 148 Treated with Bu-Flu
Posterior 95% Credible Interval
Probability of
a Beneficial EffectVariable Mean SD 2.50% 97.50%
Intercept 5.131 1.343 2.671 7.944 —
Cyto 5 bad (versus other) 0.996 0.681 20.294 2.371 0.934
Disease status 5 CR (versus not in CR) 20.092 0.712 21.488 1.313 0.448
Allo type5 sib/other rel (versus unrelated) 1.396 0.602 0.277 2.684 0.994
Age 20.055 0.025 20.109 20.009 0.009
PB Blast 5 0 (versus .0) 0.922 0.709 20.466 2.334 0.909
PB PLT 0.002 0.002 20.002 0.007 0.755
Confounded Bu-Flu (versus BuCy2) effect 1.880 0.651 0.664 3.258 0.999
R 0.166 0.049 0.087 0.277 —
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic; Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.-10 -5 0 5
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Figure 5. Posterior distributions under the lognormal regression
model for (a) NRRS, and (b) RFS of the corrected Bu-Flu versus
BuCy2 treatment effect within the 215 Bu-treated patients. In the
plot, p denotes the probability of beneficial effect of Bu-Flu versus
BuCy2, and is represented by the area of the shaded region in the re-
spective figure.lingering concern that a replacement of Cy with Flu
would represent an overall decreased treatment inten-
sity that translated into less side effects at the price of
inferior antileukemic effect, especially in subjects
with active leukemia at time of transplant [4], also ap-
pears largely unfounded, and our results indicate that
patients receiving Bu-Flu would not be at any disad-
vantage in this respect as depicted in Figure 5b. It is
important to remember that both Cy and Flu were
primarily used because of their immunosuppressive
rather than antileukemic properties, that is, to enhance
engraftment. It is true, however, that although a high
relapse rate exists in patients transplanted with chemo-
therapy-refractory leukemia and a clinically high
tumor load, the search should continue for ways to
further improve the Bu-Flu regimen. This program
should be considered primarily as a therapeutic
platform, to which other, both pre- and postgrafting
components may be added safely to improve tumor
control. Overall, it is tempting to conclude that Bu-
Flu 6 ATG represents a significant improvement for
patient safety, at least in the first (few) year(s) after al-
logeneic HSCT, because the outcome of patients
treated with Bu-Flu was significantly better than
what would be expected based on our past experience
with the BuCy2 regimen and from comparisons with
data using other conditioning programs in patients
with AML/MDS [26,47–50]. Although it was not a pri-
mary objective to compare GVHD rates after the dif-
ferent patient populations because of their disparity in
age, proportion of donors other than fully matched re-
lated donors, etc., it was noteworthy that the incidence
of GVHD among patients transplanted after Bu-Flu
(16%) with a fully matched related donor was only
half of that observed after BuCy2 (33%).
The favorable outcome of the Bu-Flu patients, in
viewof a relative long follow-up time (amedian of about
40 months) and a comparatively large number of
patients with a high median age (46 years), appears to
challenge the concept that an age above 50 or 55 years
necessitates a reduced-intensity (RIC) regimen for
682 B. S. Andersson et al.Table 5. Fitted Bayesian Log-Normal SurvivalModel for Relapse-Free Survival (RFS) in 215 Patients, Including 67 Patients Treated with BuCy2 and 148
Treated with Bu-Flu
Posterior 95% Credible Interval
Probability of
a Beneficial EffectVariable Mean SD 2.50% 97.50%
Intercept 2.856 0.659 1.575 4.145 —
Cyto 5 bad (versus other) 20.549 0.325 21.189 0.088 0.046
Disease status 5 CR (versus not in CR) 0.219 0.450 20.663 1.096 0.688
Allo type5 sib/other rel (versus unrelated) 0.398 0.331 20.248 1.046 0.889
Age 20.012 0.014 20.038 0.014 0.181
PB blast 5 0 (versus .0) 1.322 0.394 0.560 2.109 1.000
PB PLT 0.005 0.002 0.001 0.009 0.998
Confounded Bu-Flu (versus BuCy2) effect 0.042 0.356 20.652 0.760 0.547
R 0.309 0.056 0.208 0.429 —
Cyto indicates cytogenetics; PB, peripheral blood, Allo, allogeneic; Sib, sibling; Rel, related; PLT, platelet; CR, complete remission.allogeneic HSCT in AML/MDS. Finally, the Bu-Flu
data suggest that it may be time for a prospective evalu-
ation of allogeneic HSCT versus conventional induc-
tion and consolidation chemotherapy for AML/MDS
for all patients who do not have APL or core binding
factor leukemia, regardless of cytogenetic risk pattern.
Such a study should, as a minimum, cover the popula-
tion up to age 40. Previous comparisons of allogeneic
HSCT and conventional maintenance chemotherapy
mostly have relied on total body irradiation (TBI)-
based conditioning therapy, which yielded excessive
TRM without corresponding patient benefit [51,52].
In summary, the consistent and reproducible sys-
temic Bu exposure that was achieved with a parenteral
Bu formulation, when paired with Flu6 rabbit-ATG,
is likely to continue having a significant impact on
(early) posttransplant safety and survival in the studied
patient population(s).
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